China's pharmaceutical industry has entered an accelerated period of transformation, a large number of pharmaceutical companies sales costs fell

"Pharmaceutical Network Industry Dynamics" Recently, Huahai Pharmaceuticals announced its results for the first three quarters of this year.
2020, the company achieved revenue of RMB4.87 billion, up 21.41 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB841 million, up 64.23 percent year-on-year, according to the announcement.
a big increase in performance, Huahai Pharmaceuticals said this was mainly due to the "collection" of good effects and the lifting of the European sand bile raw materials.
from this, the performance of the collection of China's offshore pharmaceutical industry is very obvious, even under the impact of this year's outbreak, its performance growth momentum is very strong.
, in the overall drug market sales growth rate decline in the environment, Huahai's performance growth is rare.
But more notably, from Huahai Pharmaceuticals' third-quarter report, it can be found that the company's total operating costs increased by 3.2% year-on-year, but sales costs have shrunk significantly, by 37% year-on-year in the third quarter of 2020 and 4.1% year-on-year in the first three quarters of 2020.
is not only Huahai Pharmaceuticals, from the current disclosure of listed pharmaceutical companies in the third quarter of 2020 scheduling report, many are sales costs fell.
For example, according to Prop Pharmaceuticals' third quarter 2020 report, the company's total operating costs increased by 2.2% YoY, but the current sales expenses decreased by 39.8% compared with the previous period;
from the pharmaceutical company sales costs of the composition of the details, the organization, sponsorship of academic conferences, sales staff professional training, travel expenses, etc. , are the main content of marketing costs.
compared with the multinational pharmaceutical companies based on innovative drugs, many Chinese pharmaceutical companies, mainly generic drugs, have been relatively high sales costs.
the main reason for this situation is that most of China's pharmaceutical companies mainly to generic drugs, the production of Chinese medicine-based, product homogenization, which leads to weak pricing power, need a lot of money to promote sales.
fact, this year due to the outbreak, really on the marketing of pharmaceutical companies have had a certain impact.
But for pharmaceutical enterprises, the impact of their sales costs, from the beginning of the volume of procurement has begun to continue fermentation, transformation has become an inevitable choice for survival, sales costs gradually decreased has become an inevitable trend.
industry believes that, with the expansion of the volume of drug procurement catalog, and further promotion throughout the country, the structure of medical insurance drugs will be further optimized.
proportion of generics will shrink further, making room for innovative drugs.
the future, the continued implementation of volume procurement will make pharmaceutical companies sales costs there is more room for downward adjustment.
addition, the "fish effect" of policies such as two-vote system and volume procurement will also activate more innovation and vitality in the pharmaceutical industry.
in general, if pharmaceutical companies want to live better in the future, they must accelerate the transformation of innovation, improve drug research and development capabilities and production quality management, and further enhance overall competitiveness.
, the transformation direction of chemical and biological drugs is innovative drugs.
chinese medicine because of its theoretical basis of particularity, innovation difficulty is higher, so the classical formula-based expansion research or will be its development direction.